15,000 patients per year could benefit from higher NICE thresholds, manufacturers say

An Association of the British Pharmaceutical Industry analysis of 20 medicines appraisals conducted after the cost-effectiveness threshold was raised, revealed that half of companies said the higher threshold had a positive impact on access.
An assortment of medicines in blister packs

An increase in the cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) has improved access to new medicines for NHS patients, according to early data from the Association of the British Pharmaceutical Industry (ABPI).

In a report published on 19 November 2026, the industry trade body estimated — based on company figures — that an additional 15,426 patients per year could be eligible for medicines that might otherwise not have been available.

However, Amira Guirguis, chief scientist at the Royal College of Pharmacy, noted: “The figure of more than 15,400 a year estimates how many more patients could be eligible, not how many have received treatment.

“The next test is whether eligible patients can start treatment promptly wherever they live. Pharmacy teams can help ensure new medicines are introduced safely and patients get the monitoring and support they need.”

The ABPI report is the fifth in the trade body’s Continuous NICE Implementation Evaluation (CONNIE) series and covers 183 NICE appraisals completed up to August 2026.

NICE raised its cost effectiveness threshold in April 2026, from £20,000–£30,000 to £25,000–£35,000 per quality-adjusted life year (QALY), which is a measure of the length and quality of life a treatment adds. It was the first change in more than two decades.

Of the appraisals covered by the latest CONNIE report, 20 concluded after this change. The report revealed that in 10 of the appraisals, companies said the higher threshold had a positive impact on access. In 9 of the appraisals, NICE may not have recommended the medicine at the previous threshold, while in 1, access was extended to a wider group of patients, it added.

The report also highlighted that 6 companies said they would not have been able to launch their drug in the UK at the previous threshold, while 7 appraisals involved cancer medicines, 2 cardiovascular medicines and 1 medicine for an endocrine condition.

The figure of 10 positive recommendations enabled by the threshold change “broadly aligned” with government figures published in July 2026, which showed nine additional medicines had been approved in England and Wales because of the change, the report noted.

The government announced the NICE threshold change in December 2025, alongside what it called a “landmark” US trade agreement promising 0% tariffs on UK pharmaceutical exports.

Drug developers and patient representatives welcomed it, but several health economists told The Pharmaceutical Journal in 2025 that spending more on new medicines would mean less for other services because of the limited NHS budget.

They also said that services, such as waiting lists, community pharmacy services and medication reviews, likely represent better value per QALY.

In a press release published alongside the ABPI report, Victoria Jordan, executive director of patient access at the ABPI, said that the findings were “the first signs of what the higher threshold means for NHS patients” and called for the gains to be sustained.

“For each of those patients and their families, a new treatment can mean more time, better quality of life and greater independence,” she added.

The report also flagged areas of concern, as the top of the new range “still appears to be under-used”. The proportion of appraisals with final guidance delayed by more than a year, which is now around 1 in 5, has had a “steady increase”, it added. The report also noted the sample of appraisals since the change is small.

Rachel Power, chief executive of the Patients Association, said: “It is encouraging to see early evidence that changes to the way NICE values medicines could mean more patients having access to treatments that might otherwise have been unavailable to them. For patients living with serious or life-limiting conditions, this can make a significant difference to their lives.

“We must ensure that the benefits of these changes translate into real improvements in access and outcomes for patients, and especially for those experiencing the compounding effect of health inequalities.”

Last updated
Citation
The Pharmaceutical Journal, PJ November 2026, Vol 317, No 8015;317(8015)::DOI:10.1211/PJ.2026.1.439363

    Please leave a comment 

    You may also be interested in